News
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Zacks Investment Research on MSN5d
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback